Aclaris Therapeutics, Inc. (LON:0H8T)

Market Cap	105.32M
Revenue (ttm)	13.76M
Net Income (ttm)	-100.78M
Shares Out	n/a
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38
Average Volume	3,534
Open	1.260
Previous Close	1.239
Day's Range	1.260 - 1.270
52-Week Range	0.605 - 10.870
Beta	n/a
RSI	46.91
Earnings Date	May 8, 2025

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatmen...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 64
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H8T

Financial Performance

In 2024, Aclaris Therapeutics's revenue was $18.72 million, a decrease of -40.09% compared to the previous year's $31.25 million. Losses were -$132.07 million, 49.3% more than in 2023.

Financial numbers in USD